Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.

ABSTRACT: The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body adiposity on breast cancer onset and progression. However, an emerging but overlooked issue of clinical significance is the limited efficacy of the conventional endocrine therapies with selective estrogen receptor modulators (SERMs) or degraders (SERDs) and aromatase inhibitors (AIs) in patients affected by breast cancer and obesity. The mechanisms behind the interplay between obesity and endocrine therapy resistance are likely to be multifactorial. Therefore, what have we actually learned durin

SUBMITTER: Barone I 

PROVIDER: S-EPMC9285685 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature